PL2914264T3 - Pochodna 6-okso-1,6-dihydropirydazyny do zastosowania w leczeniu raka wątrobowokomórkowego (hcc) - Google Patents

Pochodna 6-okso-1,6-dihydropirydazyny do zastosowania w leczeniu raka wątrobowokomórkowego (hcc)

Info

Publication number
PL2914264T3
PL2914264T3 PL13776720T PL13776720T PL2914264T3 PL 2914264 T3 PL2914264 T3 PL 2914264T3 PL 13776720 T PL13776720 T PL 13776720T PL 13776720 T PL13776720 T PL 13776720T PL 2914264 T3 PL2914264 T3 PL 2914264T3
Authority
PL
Poland
Prior art keywords
hcc
dihydro
oxo
treatment
hepatocellular carcinoma
Prior art date
Application number
PL13776720T
Other languages
English (en)
Inventor
Manja Friese-Hamim
Friedhelm Bladt
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of PL2914264T3 publication Critical patent/PL2914264T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
PL13776720T 2012-11-02 2013-10-04 Pochodna 6-okso-1,6-dihydropirydazyny do zastosowania w leczeniu raka wątrobowokomórkowego (hcc) PL2914264T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12007494 2012-11-02
EP13776720.8A EP2914264B1 (en) 2012-11-02 2013-10-04 A 6-oxo-1,6-dihydro-pyridazine derivative for the use for the treatment of hepatocellular carcinoma (hcc)
PCT/EP2013/002998 WO2014067610A1 (en) 2012-11-02 2013-10-04 A 6-oxo-1,6-dihydro-pyridazine derivative for the use for the treatment of hepatocellular carcinoma (hcc)

Publications (1)

Publication Number Publication Date
PL2914264T3 true PL2914264T3 (pl) 2017-12-29

Family

ID=47143496

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13776720T PL2914264T3 (pl) 2012-11-02 2013-10-04 Pochodna 6-okso-1,6-dihydropirydazyny do zastosowania w leczeniu raka wątrobowokomórkowego (hcc)

Country Status (26)

Country Link
US (1) US20150283137A1 (pl)
EP (1) EP2914264B1 (pl)
JP (1) JP6255028B2 (pl)
KR (1) KR102131588B1 (pl)
CN (1) CN104768553A (pl)
AR (1) AR093318A1 (pl)
AU (1) AU2013339823B2 (pl)
BR (1) BR112015008279A2 (pl)
CA (1) CA2890273C (pl)
DK (1) DK2914264T3 (pl)
ES (1) ES2646913T3 (pl)
HK (1) HK1211869A1 (pl)
HR (1) HRP20171295T1 (pl)
HU (1) HUE035483T2 (pl)
IL (1) IL238536B (pl)
LT (1) LT2914264T (pl)
MX (1) MX354518B (pl)
NO (1) NO2914264T3 (pl)
PL (1) PL2914264T3 (pl)
PT (1) PT2914264T (pl)
RS (1) RS56485B1 (pl)
RU (1) RU2650679C2 (pl)
SG (1) SG11201503214YA (pl)
SI (1) SI2914264T1 (pl)
WO (1) WO2014067610A1 (pl)
ZA (1) ZA201503924B (pl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114698541A (zh) 2013-08-14 2022-07-05 有限会社日本通商 水栽培系统和设置有水栽培系统的植物工厂
PL3996688T3 (pl) * 2019-07-10 2024-02-12 Merck Patent Gmbh Preparat farmaceutyczny
JP2022551672A (ja) * 2019-10-14 2022-12-12 オラテック セラピューティクス リミティド ライアビリティ カンパニー 乳癌治療法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005057924A1 (de) * 2005-12-05 2007-06-06 Merck Patent Gmbh Pyridazinonderivate
DE102007032507A1 (de) * 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
WO2010078897A1 (en) * 2009-01-08 2010-07-15 Merck Patent Gmbh Novel polymorphic forms of 3-(1-{3-[5-(1-methyl-piperidin-4ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride salt and processes of manufacturing thereof

Also Published As

Publication number Publication date
HK1211869A1 (en) 2016-06-03
IL238536A0 (en) 2015-06-30
MX2015005265A (es) 2015-07-17
PT2914264T (pt) 2017-11-14
HUE035483T2 (hu) 2018-05-02
AR093318A1 (es) 2015-05-27
SG11201503214YA (en) 2015-05-28
CA2890273C (en) 2021-10-26
MX354518B (es) 2018-03-08
WO2014067610A1 (en) 2014-05-08
IL238536B (en) 2019-01-31
JP2015536957A (ja) 2015-12-24
CN104768553A (zh) 2015-07-08
AU2013339823A1 (en) 2015-06-18
RU2650679C2 (ru) 2018-04-17
LT2914264T (lt) 2017-11-10
DK2914264T3 (en) 2017-09-11
US20150283137A1 (en) 2015-10-08
RU2015120692A (ru) 2016-12-27
AU2013339823B2 (en) 2018-01-04
ZA201503924B (en) 2020-11-25
KR20150079942A (ko) 2015-07-08
SI2914264T1 (sl) 2017-12-29
NO2914264T3 (pl) 2018-01-06
ES2646913T3 (es) 2017-12-18
EP2914264A1 (en) 2015-09-09
RS56485B1 (sr) 2018-01-31
BR112015008279A2 (pt) 2017-07-04
JP6255028B2 (ja) 2017-12-27
KR102131588B1 (ko) 2020-07-08
EP2914264B1 (en) 2017-08-09
CA2890273A1 (en) 2014-05-08
HRP20171295T1 (hr) 2017-10-20

Similar Documents

Publication Publication Date Title
EP3685870B8 (en) Zone heating for respiratory circuits
IL237275A0 (en) Compounds for the treatment of paramoxovirus viral infections
GB201223466D0 (en) Time-based authentication
LT2552438T (lt) Hepatoceliulinės karcinomos gydymo būdai
PL2890257T3 (pl) Inhalator
IL235825A0 (en) inhaler
AU345542S (en) Inhaler
GB201219873D0 (en) Diverticulitis treatment
ZA201307476B (en) New pyridazinone and pyridone compounds
EP3107538A4 (en) Combination therapy for hepatocellular carcinoma
GB2515783B (en) Process for preparing clomazone, a form and use of the same
IL235693B (en) Biological therapy for the treatment of a malignant tumor of liver cells
GB2504509B (en) Phase - locked loop
ZA201503924B (en) A 6-oxo-1,6-dihydro-pyridazine derivative for the use for the treatment of hepatocellular carcinoma (hcc)
PL2954114T3 (pl) Płyta do obróbki dla urządzenia do obróbki odzieży
GB201307348D0 (en) Garment for therapeutic treatment
SG11201605501RA (en) A 6-oxo-1,6-dihydro-pyridazine derivative for the use for the treatment of renal cell carcinoma (rcc)
GB2553253B (en) A form of clomazone, a process for preparing the same and use of the same
GB201319234D0 (en) Method for diagnosing hepatocellular carcinoma (HCC)
GB201212604D0 (en) New treatment
GB201215527D0 (en) Compounds for the treatment of muscular dystrophy
HUE043375T2 (hu) Kezelõlap ruházati kezelõ berendezéshez
GB201108311D0 (en) The grabbgo. Hot hand protector